The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Providing Translatable Evidence To Advance Prevention And Management Of COPD: A Longitudinal Study From The 1st To 7th Decade Of Life
Funder
National Health and Medical Research Council
Funding Amount
$2,893,320.00
Summary
Chronic obstructive pulmonary disease (COPD) makes breathing difficult and reduces wellbeing. People are more likely to get COPD from the age of 60 years, but we do not know why and who. Our study will develop tools to identify early who will develop COPD by 60 years. We will also develop a tool to identify 60-year-old individuals whose lung function is declining faster than normal. These findings will help us to better prevent and manage COPD.
Characterisation Of Emerging New Signaling Networks That Underlie COPD Phenotypes
Funder
National Health and Medical Research Council
Funding Amount
$696,966.00
Summary
Incurable diseases such as chronic obstructive pulmonary disease are becoming increasingly prevalent in Australia’s aging population and new therapies are urgently needed. We have discovered a possible cause of severe emphysema and developed a novel method to image functional changes in the diseased lung. Using advanced molecular and imaging techniques we are now probing for ways to turn this discovery into effective treatments for this fatal disease.
Transition From Childhood To Adult Asthma: Predicting Persistent And Adult-onset Asthma In Young Adults In The Raine Longitudinal Birth Cohort
Funder
National Health and Medical Research Council
Funding Amount
$1,018,496.00
Summary
While many children grow out of their asthma a significant number continue to have asthma in later life. The Raine community birth cohort has followed newborn infants from birth and has contributed to our understanding of how asthma develops throughout childhood. The proposed project aims to assess those factors that contribute to the persistence of asthma throughout childhood in into early adult life in the as well as investigate the predictors of adult onset asthma at 23 years of age.
Targeting Macrophage Subtypes As A Strategy For Chronic Inflammatory Lung Disease Therapy
Funder
National Health and Medical Research Council
Funding Amount
$660,471.00
Summary
Researchers in Melbourne have discovered a possible cause of severe emphysema. Using disease models, patients’ samples and advanced genetic techniques they are now searching for ways to turn this discovery into effective treatments for this disease which is currently fatal and incurable.
The Role Of Long Non-coding RNA In Regulating Lung Immunity And Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Chronic inflammatory diseases of the lung, asthma and COPD, account for significant morbidity and poor quality of life in our community. Respiratory infection is one of the major causes of exacerbation and affects 50-80% of both asthma and COPD patients admitted to hospital. These groups of patients are steroid resistance and difficult to manage. Our aim is to identify novel molecules important in regulating inflammation and to target them therapeutically to treat these patients.
Targeting Oxidant-dependent Mechanisms That Drive COPD And Its Co-morbidities
Funder
National Health and Medical Research Council
Funding Amount
$741,343.00
Summary
Chronic obstructive pulmonary disease (COPD) is a lung disease that is the 4th leading cause of death worldwide. There is currently no effective therapy to treat people with COPD, which costs the Australian community over $8.8 billion/year. Much of the disease burden and health care costs in COPD is associated with the management of its comorbidities (i.e other chronic medical conditions such as heart disease). This project will develop novel therapies to treat COPD and its comorbidities.
Asthma is a National Health Priority in Australia. This project follows the major international study of asthma and allergic diseases in adults. We will re-examine people who have taken part in previous studies in Melbourne. The project also surveys people of the same age currently living in the same area. Participants complete a short postal questionnaire. In the follow-up group, responders complete a more extensive questionnaire and come to our laboratory for clinical assessments.
A Comprehensive Self-Management Programme For Chronic Obstructive Pulmonary Disease In The Community
Funder
National Health and Medical Research Council
Funding Amount
$391,610.00
Summary
Chronic obstructive pulmonary disease (COPD) is the third leading cause of burden of disease in Australia. It has a major impact on sufferers, their carers and society. This study introduces a new model of community care, based on case management, mentoring to improve self-efficacy and information systems to deliver information and closely monitor disease status. This will improve the quality of life of sufferers, develop healthcare networks and decrease healthcare utilisation.
Development Of New Therapies For Respiratory Diseases And Infection
Funder
National Health and Medical Research Council
Funding Amount
$847,490.00
Summary
Prof Hansbro’s group have developed world 1st experimental models of emphysema, severe asthma infection and lung cancer. He uses them to further our understanding of these untreatable diseases. This has led to the development of new potential therapeutic approaches. Now, in discovery programs he will expand studies of pathogenesis to identify new therapeutic targets these diseases. In development and translational programs he will progress new therapies towards clinical application.